LIDDS has announced that an agreement has been signed with Johnson & Johnson Enterprise Innovation to develop an oncology product based on the NanoZolid technology for an undisclosed indication.
“I am pleased that we have signed this exciting collaboration,” says Monica Wallter, CEO of LIDDS in the company’s press release. “LIDDS favorable and clinically validated results using the NanoZolid platform with different types of pharmaceutical substances, forms a bedrock for new and innovative oncology products.”
Read more: LIDDS to apply for listing on Nasdaq Stockholm Main Market
Photo of Monica Wallter: LIDDS
Read more: Mini-interview: Monica Wallter, CEO of LIDDS
